Alcidion Group Ltd (ASX: ALC) Share Price and News
Price
$0.084
Movement
0.001 (+1.21%)
as at 24 Apr - Closed (20 mins delayed)
52 Week Range
$0.045 - $0.115
1 Year Return
+55.56%
Alcidion Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
$0.084
Day Change
0.001 (+1.21%)
52 Week Range
$0.045 - $0.115
Yesterday's Close
$0.083
Today's Open
$0.085
Days Range
$0.084 - $0.089
Volume
1,458,843
Avg. Volume (1 month)
1,265,555
Turnover
$125,797
as at 24 Apr - Closed
Alcidion Group Ltd (ASX: ALC)
Latest News

Earnings Results
Up 94% in a year, why is this ASX healthcare stock rocketing again today?

Healthcare Shares
Guess which ASX healthcare stock is rocketing 25% on big UK news

Healthcare Shares
2 ASX healthcare shares outperforming on big news

Healthcare Shares
Guess which ASX healthcare stock just rocketed 46% on major news!

Healthcare Shares
Why is the Alcidion share price crashing 27% to a 52-week low?

Broker Notes
400% organic growth in 3 years: The ASX small-cap Cyan is pumped about

Opinions
An unloved ASX stock I'm considering buying with $5,000 in August

Earnings Results
Alcidion share price charges 9% ahead on record quarter

Small Cap Shares
'Upside surprise': 2 small-cap ASX shares ready to break out

Broker Notes
Leading brokers name 3 ASX shares to buy today

Growth Shares
ASX shares: Invest in these 2 stocks for a legit chance at $1 million

Share Market News
3 ASX All Ordinaries shares getting hammered on quarterly updates
Frequently Asked Questions
-
No, Alcidion does not pay dividends at this time.
-
Alcidion listed on the ASX on 24 June 2011.
ALC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
22nd Apr 2025 2025-04-22T08:22:59 | Q3 FY25 Quarterly Activities Report and Appendix 4C | YesNo | 8:22am | 8 | 562k |
16th Apr 2025 2025-04-16T11:21:47 | Alcidion Q3 FY25 Results and Investor Webcast Notification | YesNo | 11:21am | 2 | 158k |
16th Apr 2025 2025-04-16T11:12:57 | Notification regarding unquoted securities - ALC | YesNo | 11:12am | 6 | 16k |
15th Apr 2025 2025-04-15T08:27:25 | Initial Director's Interest Notice | YesNo | 8:27am | 3 | 317k |
15th Apr 2025 2025-04-15T08:21:00 | Appointment of Non-Executive Director | YesNo | 8:21am | 2 | 184k |
12th Mar 2025 2025-03-12T08:18:33 | Investor Roadshow Presentation | YesNo | 8:18am | 37 | 4.4M |
7th Mar 2025 2025-03-07T08:21:46 | Coffee Microcaps Presentation | YesNo | 8:21am | 19 | 2.1M |
4th Mar 2025 2025-03-04T16:19:43 | Change of Director's Interest Notice | YesNo | 4:19pm | 2 | 163k |
4th Mar 2025 2025-03-04T16:15:23 | Share Sale by Managing Director & CEO | YesNo | 4:15pm | 1 | 133k |
27th Feb 2025 2025-02-27T20:28:38 | Ceasing to be a substantial holder | YesNo | 8:28pm | 2 | 139k |
About Alcidion Group Ltd
Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.
The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.
Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems. Other products include Smartpage and Patientrack software.
Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.
ALC Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
23 Apr 2025 | $0.08 | $0.00 | 0.00% | 1,773,212 | $0.08 | $0.09 | $0.08 |
22 Apr 2025 | $0.08 | $0.00 | 0.00% | 3,251,333 | $0.08 | $0.09 | $0.08 |
17 Apr 2025 | $0.08 | $0.00 | 0.00% | 1,316,903 | $0.08 | $0.08 | $0.07 |
16 Apr 2025 | $0.08 | $0.00 | 0.00% | 908,707 | $0.07 | $0.08 | $0.07 |
15 Apr 2025 | $0.07 | $0.00 | 0.00% | 709,027 | $0.08 | $0.08 | $0.07 |
14 Apr 2025 | $0.08 | $0.00 | 0.00% | 500,207 | $0.07 | $0.08 | $0.07 |
11 Apr 2025 | $0.07 | $-0.01 | -12.99% | 522,716 | $0.08 | $0.08 | $0.07 |
10 Apr 2025 | $0.08 | $0.01 | 14.49% | 2,068,456 | $0.07 | $0.08 | $0.07 |
09 Apr 2025 | $0.07 | $0.00 | 0.00% | 261,651 | $0.07 | $0.07 | $0.07 |
08 Apr 2025 | $0.07 | $0.00 | 0.00% | 933,738 | $0.07 | $0.07 | $0.07 |
07 Apr 2025 | $0.07 | $0.00 | 0.00% | 1,886,767 | $0.07 | $0.07 | $0.06 |
04 Apr 2025 | $0.07 | $0.00 | 0.00% | 3,628,414 | $0.08 | $0.08 | $0.07 |
03 Apr 2025 | $0.08 | $-0.01 | -12.20% | 2,120,744 | $0.08 | $0.08 | $0.08 |
02 Apr 2025 | $0.08 | $0.00 | 0.00% | 305,981 | $0.08 | $0.08 | $0.08 |
01 Apr 2025 | $0.08 | $0.00 | 0.00% | 1,226,422 | $0.08 | $0.09 | $0.08 |
31 Mar 2025 | $0.08 | $0.00 | 0.00% | 1,429,874 | $0.09 | $0.09 | $0.08 |
28 Mar 2025 | $0.09 | $0.00 | 0.00% | 406,650 | $0.08 | $0.09 | $0.08 |
27 Mar 2025 | $0.08 | $0.00 | 0.00% | 1,126,212 | $0.08 | $0.09 | $0.08 |
26 Mar 2025 | $0.08 | $0.00 | 0.00% | 1,284,514 | $0.08 | $0.08 | $0.08 |
25 Mar 2025 | $0.08 | $0.00 | 0.00% | 452,721 | $0.08 | $0.09 | $0.08 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
04 Mar 2025 | Katrina (Kate) Doyle (Quirke) | Sell | 5,000,000 | $425,000 |
Off-market trade.
|
26 Apr 2024 | Daniel Sharp | Transfer | 800,000 | $44,000 |
Off-market transfer. Assuming off market transfer of shares
|
26 Apr 2024 | Daniel Sharp | Buy | 250,000 | $13,070 |
On-market trade.
|
26 Apr 2024 | Daniel Sharp | Transfer | 800,000 | $44,000 |
Off-market transfer. Assuming off market transfer of shares
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Ms Rebecca Jayne Wilson | Non-Executive DirectorNon-Executive Chairman | Jul 2017 |
Ms Wilson is a company director and Board advisor in Australia, UK and US and has more than 25 years of experience working within the healthcare, technology and life science sectors. She provides advice on complex stakeholder communication, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She has mature governance and risk management experience.
|
Mr William (Bill) Smart | Non-Executive Director | Oct 2024 |
Mr Smart is a global digital health leader at both an operational and non-executive level having recently stepped down as the Global Director of External Relations, Dedalus Group, a global digital health company. Based in the United Kingdom, Will is currently Digital Non-Executive Director, Great Western Hospitals NHS Foundation Trust and was previously the CIO for Health and Social Care for England. He has held executive roles in several NHS Trusts including as Group Chief Information Officer, Royal Free London NHS Foundation Trust. In his capacity as Digital Non-Executive Director, Great Western Hospitals NHS Foundation Trust, Will is a member of the Acute Hospitals Alliance EPR Joint Committee responsible for overseeing the implementation of a new EPR across Great Western, Royal University Hospital, and Salisbury Trusts. Will is also a Director of CareTech Partners Limited providing digital advisory and consultancy support to public and private organisations and a member of the Health and Social Care Council at TechUK, a member organisation that represents and supports the UK technology sector and works with government, regulators and stakeholders.
|
Ms Victoria Weekes | Non-Executive Director | Sep 2021 |
Ms Weekes is a non-executive director with experience across a diverse range of industries built on a successful executive career in investment markets and financial services. Victorias 30 years of experience in the finance and banking sector includes Csuite roles as a Managing Director at Citigroup and Executive General Manager at Westpac. As the immediate past Chair of the Sydney Local Health District, Victoria has a deep understanding of the healthcare sector where she served as Chair of its Education & Research Committee and Deputy Chair. She is the chairman of risk committee.
|
Ms Katrina (Kate) Elizabeth Doyle (Quirke) | Chief Executive OfficerExecutive DirectorManaging Director | Jul 2018 |
Ms Doyle has been CEO of Alcidion since 2018, prior to which she was CEO of MKM Health until it was acquired by Alcidion. She has been involved in large systems procurements and implementations of healthcare information technology across Australia, United Kingdom, New Zealand and Southeast Asia. Her background involves holding leading management roles at some of the largest healthcare software firms where she has had an impact on strategic product direction across
the health sector and believes astute application of information technology will support the transformation of healthcare delivery worldwide. |
Mr Daniel Sharp | Non-Executive Director | Sep 2021 |
Mr Sharp has over 25 years senior executive experience in investment banking and corporate finance. From 2012-2020, Daniel was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Daniel headed the corporate finance division at two of Australia's independent Investment Banking/Stockbroking firms. He is closely connected to strong networks of institutional, family office and high net worth investors both in Australia and overseas. He is also a member of risk committee.
|
Professor Andrew Way | Non-Executive Director | Apr 2025 |
Prof Way brings a wealth of experience to the Board of Alcidion, having served as the Chief Executive of Alfred Health from 2009 to 2024 as well as having held several senior positions in the England National Health Service (NHS). Andrew also led the development of Monash Partners, Victorias first Academic Health Science Centre and was appointed as an Adjunct Clinical Professor in the School of Public Health and Preventative Medicine, Faculty of Medicine Nursing and Health Sciences, Monash University in 2015. In addition to his senior leadership roles, Professor Way holds several non-executive and advisory roles both in Australia and internationally including Chair of the Department of Healths HSV (Health Services Victoria) Board.
|
Mr Michael Sapountzis | Company Secretary | Mar 2019 |
-
|
Matthew Gepp | Chief Financial Officer |
-
|
|
Michael Sapountzis | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
J P Morgan Nominees Australia Pty Limited | 156,589,750 | 11.66% |
Mr Malcolm Pradhan | 134,582,403 | 10.02% |
Bond Street Custodians Limited <Salter D79836 A/C> | 73,000,000 | 5.44% |
Mr Raymond Howard Blight | 68,801,020 | 5.12% |
Rewmicman Pty Ltd <Smallman Family A/C> | 28,810,441 | 2.15% |
Mrs Katrina Elizabeth Doyle | 27,793,199 | 2.07% |
Caledonia Nominees Pty Ltd <Caledonia A/C> | 19,976,377 | 1.49% |
MNMD Pty Ltd <Quirke Super Fund A/C> | 19,668,086 | 1.47% |
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 17,189,236 | 1.28% |
Bond Street Custodians Limited <RSALTE - D62375 A/C> | 13,999,000 | 1.04% |
Mr Dean Anthony Mackenzie | 13,143,801 | 0.98% |
Mr Paul John Van Dyk | 12,300,000 | 0.92% |
Sandhurst Trustees Ltd <Cyan C3G Fund A/C> | 10,469,114 | 0.78% |
Citicorp Nominees Pty Limited | 10,272,574 | 0.77% |
Rangiora London Pty Limited <Rangiora-London A/C> | 7,800,000 | 0.58% |
Emerald Shares Pty Limited <Emerald Unit A/C> | 7,100,000 | 0.53% |
Mr Vivek Ramakrishnan and Miss Nisha Srinivasan | 7,021,913 | 0.52% |
Finclear Services Pty Ltd <Superhero Securities A/C> | 6,807,539 | 0.51% |
Hudson Retirement Pty Ltd <Seagulls Super A/C> | 6,524,244 | 0.49% |
Webzone Holdings Pty Ltd | 5,820,000 | 0.42% |